<DOC>
	<DOCNO>NCT02150317</DOCNO>
	<brief_summary>The aim study compare outcomes Transarterial Chemoembolization ( TACE ) follow Sorafenib TACE alone patient advance hepatocellular carcinoma .</brief_summary>
	<brief_title>Transarterial Chemoembolization ( TACE ) Plus Sorafenib Versus TACE Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male female patient &gt; 18 year &lt; =70 year age . least 2 radiologic image show characteristic feature hepatocellular carcinoma cytologic/histologic evidence . tumor liver radiologically definable vascular invasion extrahepatic metastasis . Criteria liver function : Child AB level , serum bilirubin ≤ 1.5 time upper limit normal value , alanine aminotransferase aspartate aminotransferase ≤ 2 time upper limit normal value . No dysfunction major organ ; Blood routine , kidney function , cardiac function lung function basically normal . Hb ≥90g/L , white blood cell count ≥3.000 cells/mm³ , platelet ≥80.000 cells/mm³ Patients understand trial sign information consent Patients apparent cardiac , pulmonary , cerebral renal dysfunction , may affect treatment liver cancer . Patients disease may affect treatment mention . Patients medical history malignant tumor . Subjects participate clinical trial . liver function : Child C. pathological evidence hepatocellular carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Chemoembolization , Therapeutic</keyword>
	<keyword>Sorafenib</keyword>
</DOC>